Even as Amylyx’s ALS drug gains steam in the U.S. after a long-awaited FDA approval, the company is struggling with regulatory hurdles overseas.

This week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against an approval for the second time this year.

The med, called Albrioza in Europe and Relyvrio in the U.S., was shot down at CHMP—again—after a formal re-examination of the committee’s initial negative opinion in June.

Phase 2 data from its Centaur trial, which formed the basis of the FDA’s 2022 approval decision, didn’t sway the European regulators.

Now, the company is focused on its global phase 3 Pheonix study, which has an anticipated topline readout in mid-2024 and will provide further data on the drug’s efficacy and safety profile, Amylyx said in a statement.

The 48-week study has enrolled 664 participants across 69 sites in Europe and the U.S. If the data support an application, the company would try again for EU approval “as quickly as possible,” Amylyx said.

Meanwhile, after CHMP’s negative recommendation, it’s up to the European Commission to make the final call on the Albrioza application. The EC’s decision is expected by the end of 2023.

“ALS has no geographical boundaries, and we are working with urgency toward providing timely, broad, and sustainable access to AMX0035 for eligible people living with ALS who may benefit,” Amylyx’s co-CEOs Joshua Cohen and Justin Klee said in a statement.

In the U.S., the company won approval last September after overcoming several prior regulatory setbacks.

So far, Relyvrio is putting on a strong commercial show in the U.S., generating sales of $400 million since its launch. The med is priced at about $158,000 per year and has gained widespread insurance coverage, Amylyx execs have said.

Source: https://www.fiercepharma.com/pharma/amylyxs-als-drug-relyvrio-rebuffed-eus-chmp-again
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.